GEN Exclusives

More »

GEN News Highlights

More »
Aug 30, 2012

Charles River Buys Accugenix for $17M

  • Charles River Laboratories acquired cGMP contract microbial identification and typing firm Accugenix for $17 million in cash. Charles River says the buyout will strengthen its own endotoxin and microbial detection (EMD) product portfolio by providing clients with microbial detection services for manufacturing in the biopharmaceutical, medical device, and other sectors.

    “The acquisition of Accugenix is the first step in our broader strategy to become the premier provider of rapid microbial and endotoxin detection products and services to the biopharmaceutical industry,” states James C. Foster, chairman, president and CEO at Charles River. “Over the next several years we intend to enhance our capabilities through both product extensions and acquisitions.”

    Accugenix specializes in the provision of bacterial and fungal identification and strain typing of services to a range of manufacturing industries. The firm says its library databases enable the identification of over 5,000 species.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Patients Access to Experimental Medicines?

More »